S&P 500   4,615.19 (-0.86%)
DOW   34,809.09 (-0.93%)
QQQ   400.46 (+0.19%)
AAPL   164.47 (+2.64%)
MSFT   337.52 (+0.26%)
FB   334.84 (-0.94%)
GOOGL   2,903.65 (-0.24%)
AMZN   3,568.73 (+0.20%)
TSLA   1,163.00 (+2.29%)
NVDA   331.96 (-0.54%)
BABA   129.54 (-1.57%)
NIO   40.71 (+0.62%)
CGC   10.82 (-2.17%)
AMD   163.30 (+0.86%)
GE   96.21 (-2.23%)
MU   86.16 (+0.02%)
T   23.04 (-3.56%)
F   19.56 (-0.56%)
DIS   145.79 (-1.37%)
ACB   6.42 (-0.31%)
AMC   35.46 (-3.75%)
PFE   53.73 (+2.54%)
BA   197.21 (-0.65%)
S&P 500   4,615.19 (-0.86%)
DOW   34,809.09 (-0.93%)
QQQ   400.46 (+0.19%)
AAPL   164.47 (+2.64%)
MSFT   337.52 (+0.26%)
FB   334.84 (-0.94%)
GOOGL   2,903.65 (-0.24%)
AMZN   3,568.73 (+0.20%)
TSLA   1,163.00 (+2.29%)
NVDA   331.96 (-0.54%)
BABA   129.54 (-1.57%)
NIO   40.71 (+0.62%)
CGC   10.82 (-2.17%)
AMD   163.30 (+0.86%)
GE   96.21 (-2.23%)
MU   86.16 (+0.02%)
T   23.04 (-3.56%)
F   19.56 (-0.56%)
DIS   145.79 (-1.37%)
ACB   6.42 (-0.31%)
AMC   35.46 (-3.75%)
PFE   53.73 (+2.54%)
BA   197.21 (-0.65%)
S&P 500   4,615.19 (-0.86%)
DOW   34,809.09 (-0.93%)
QQQ   400.46 (+0.19%)
AAPL   164.47 (+2.64%)
MSFT   337.52 (+0.26%)
FB   334.84 (-0.94%)
GOOGL   2,903.65 (-0.24%)
AMZN   3,568.73 (+0.20%)
TSLA   1,163.00 (+2.29%)
NVDA   331.96 (-0.54%)
BABA   129.54 (-1.57%)
NIO   40.71 (+0.62%)
CGC   10.82 (-2.17%)
AMD   163.30 (+0.86%)
GE   96.21 (-2.23%)
MU   86.16 (+0.02%)
T   23.04 (-3.56%)
F   19.56 (-0.56%)
DIS   145.79 (-1.37%)
ACB   6.42 (-0.31%)
AMC   35.46 (-3.75%)
PFE   53.73 (+2.54%)
BA   197.21 (-0.65%)
S&P 500   4,615.19 (-0.86%)
DOW   34,809.09 (-0.93%)
QQQ   400.46 (+0.19%)
AAPL   164.47 (+2.64%)
MSFT   337.52 (+0.26%)
FB   334.84 (-0.94%)
GOOGL   2,903.65 (-0.24%)
AMZN   3,568.73 (+0.20%)
TSLA   1,163.00 (+2.29%)
NVDA   331.96 (-0.54%)
BABA   129.54 (-1.57%)
NIO   40.71 (+0.62%)
CGC   10.82 (-2.17%)
AMD   163.30 (+0.86%)
GE   96.21 (-2.23%)
MU   86.16 (+0.02%)
T   23.04 (-3.56%)
F   19.56 (-0.56%)
DIS   145.79 (-1.37%)
ACB   6.42 (-0.31%)
AMC   35.46 (-3.75%)
PFE   53.73 (+2.54%)
BA   197.21 (-0.65%)
NASDAQ:LUCD

Lucid Diagnostics Stock Forecast, Price & News

$8.06
+0.10 (+1.26%)
(As of 11/30/2021 10:36 AM ET)
Add
Compare
Today's Range
$7.90
$8.11
50-Day Range
N/A
52-Week Range
$7.37
$13.52
Volume
41 shs
Average Volume
210,537 shs
Market Capitalization
$296.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive LUCD News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.


Lucid Diagnostics logo

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUCD
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$296.69 million
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

782nd out of 1,390 stocks

Surgical & Medical Instruments Industry

88th out of 127 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Lucid Diagnostics (NASDAQ:LUCD) Frequently Asked Questions

Is Lucid Diagnostics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lucid Diagnostics stock.
View analyst ratings for Lucid Diagnostics
or view top-rated stocks.

What price target have analysts set for LUCD?

4 brokerages have issued 1 year price objectives for Lucid Diagnostics' stock. Their forecasts range from $14.00 to $21.00. On average, they anticipate Lucid Diagnostics' share price to reach $17.50 in the next twelve months. This suggests a possible upside of 117.1% from the stock's current price.
View analysts' price targets for Lucid Diagnostics
or view top-rated stocks among Wall Street analysts.

When did Lucid Diagnostics IPO?

(LUCD) raised $75 million in an IPO on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

What is Lucid Diagnostics' stock symbol?

Lucid Diagnostics trades on the NASDAQ under the ticker symbol "LUCD."

When did Lucid Diagnostics' quiet period expire?

Lucid Diagnostics' quiet period expired on Tuesday, November 23rd. Lucid Diagnostics had issued 5,000,000 shares in its public offering on October 14th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. During Lucid Diagnostics' quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Lucid Diagnostics?

Shares of LUCD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lucid Diagnostics' stock price today?

One share of LUCD stock can currently be purchased for approximately $8.06.

How much money does Lucid Diagnostics make?

Lucid Diagnostics has a market capitalization of $296.69 million.

How many employees does Lucid Diagnostics have?

Lucid Diagnostics employs 2,021 workers across the globe.

What is Lucid Diagnostics' official website?

The official website for Lucid Diagnostics is www.luciddx.com.

How can I contact Lucid Diagnostics?

The company can be reached via phone at 212-949-4319 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.